TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Obesity, Oral Contraception, and Ovarian Suppression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18-35~* Body Mass Index (BMI) 19-24.9 or 30-39.9 kg/m\^2~* Willing to take birth control pills for 3-4 months~* Recent spontaneous pregnancy or cyclic menses~Exclusion Criteria:~* Contraindications to hormonal contraceptives~* Oophorectomy/Polycystic ovary syndrome (PCOS)~* Taken oral contraceptives to regulate menses recently~* Weight reduction surgery~* Used Depo-Provera within the last 12 months~* Pregnant or currently breastfeeding~* Desiring pregnancy within the next 4 months~* Unable to make study visit commitment~* Previous participation in this study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Normal Weight group (Type: ACTIVE_COMPARATOR): Participants with a BMI of 19-24.9 kg/m\^2
- Obese group (Type: ACTIVE_COMPARATOR): Participants with a BMI of 30-39.9 kg/m\^2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Folinic Acid to Improve Mental Development of Children With Down Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Down syndrome without mosaicism~* age 3 to 30 months~* weight over 4 kg~* possible assessment by the revised Brunet-Lezine scale~Exclusion Criteria:~* history of leukemia~* West syndrome or non-stable epilepsy~* non-stable thyroxin treatment

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 30 Months
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female healthy children and adolescents aged \> 2 months to \< 18 years at the time of first vaccination.~* Written informed consent by the subject's legal representative(s), according to local requirements, and written informed assent of the subject, if applicable.~* Female subjects: either no childbearing potential or negative pregnancy test, for females after menarche willingness to practice a reliable method of contraception.~Exclusion Criteria:~* Clinical manifestation of Japanese Encephalitis~* History of Flavivirus vaccination (including any investigational vaccines)~* History of vaccination with HAVRIX®720 and/or Prevnar®~* History of immunodeficiency or immunosuppressive therapy~* Known HIV, HBV or HCV infection~* History of hypersensitivity reactions to other vaccines~* Acute febrile infection at each visit during which the subject receives a vaccination~* Active or passive immunization within 2 weeks prior to the first IC51 vaccination and up to the second IC51 vaccination.

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- IC51 0.5 mL (Type: EXPERIMENTAL): Japanese Encephalitis Vaccine 6mcg im. at day 0 and day 28
- IC51 0.25 mL (Type: EXPERIMENTAL): Japanese Encephalitis Vaccine 3mcg im. at day 0 and day 28
- Havrix 720 (Type: ACTIVE_COMPARATOR): Havrix®720 0.5 ml im. at day 0 and month 7
- Prevnar (Type: ACTIVE_COMPARATOR): Prevnar 0.5 ml im. at day 0 and day 56 and month 7 or 0.5 ml im. at day 0, day 28 and day56 and month 7-13

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Novel MRI ANd Biomarkers in GOlimumab-treated Patients With Axial Spondyloarthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Axial spondyloarthritis according to the Assessment of Spondyloarthritis International Society (ASAS) classification criteria for axial spondyloarthritis~* Sacroiliitis on conventional X-rays or Magnetic Resonance Imaging (MRI).~* Disease activity assessed by Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) \>40 mm despite treatment with Non-Steroidal Anti-Inflammatory Drugs (NSAID).~* Clinical indication for tumor necrosis factor (TNF) inhibitor treatment by the treating physician.~Exclusion Criteria:~* No contraindications for TNF inhibitor~* No contraindications for MRI~* No contraindications in participation in a study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: None): Treatment: Injection Golimumab 50 mg every month on the same date

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of a FAAH-Inhibitor to Treat Cannabis Withdrawal

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male~2. Ages 18-55 (inclusive)~3. Cannabis Dependence~Exclusion Criteria:~1. Allergies or intolerance to FAAH-Inhibitors~2. Current significant medical or other comorbidities

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- PF-04457845 (Type: ACTIVE_COMPARATOR): 2/3 of subjects will be randomized to fatty acid amide hydrolase (FAAH) inhibitor 4mg
- Placebo (sugar pill) (Type: PLACEBO_COMPARATOR): 1/3 of subjects will be randomized to placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of OMS302 in Subjects Undergoing Unilateral Cataract Extraction With Lens Replacement (CELR)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Competent and willing to voluntarily provide informed consent~* 18 years of age or older~* In good general health needing to undergo cataract extraction with lens replacement surgery in one eye, under topical anesthesia~* Other inclusion criteria to be evaluated by the investigator~Exclusion Criteria:~* No allergies to the medications and/or the active ingredients of any of the study medications~* No medications with the same activities as the of the active ingredients in OMS302 for defined time intervals prior to and after surgery~* No other significant eye injuries, eye conditions or general medical conditions likely to interfere with the evaluation of the study medication~* Other exclusion criteria to be evaluated by the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OMS302 Solution (Type: EXPERIMENTAL): OMS302 Solution
- OMS302 Mydriatic Solution (Type: EXPERIMENTAL): OMS302 Mydriatic Solution
- OMS302 Anti-inflammatory Solution (Type: EXPERIMENTAL): OMS302 Anti-inflammatory Solution
- Balanced Salt Solution (BSS) Solution (Type: PLACEBO_COMPARATOR): Balanced Salt Solution (BSS) Solution

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Crystalline Glucosamine Sulfate Therapy in Hand Osteoarthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Mono or bilateral primary HOA and concomitant knee OA, according to the American College of Rheumatology (ACR) criteria~* Treatment for at least 6 consecutive months with crystalline GS at the daily dose of 1500 mg in addition to the conventional therapy or with usual care alone.~* HOA symptoms duration for at least 3 months defined as global hand pain score superior to 40 mm on a 0-100 VAS and a FIHOA score of at least 6.~* Radiographic evidence of HOA within the previous 6 months with a radiological score of II-III (using the Kellgren method).~Exclusion Criteria:~* Erosive Osteoarthritis of the hand~* Medical history of any inflammatory joint disease, septic arthritis, previous articular fracture of the concerned joints, monarticular post-traumatic OA of the finger, a history or the presence of any other rheumatic diseases that could cause secondary OA, such as hemochromatosis.~* Ongoing therapy with opioid analgesics and any kind of topical treatment~* Therapy with SYSADOAs other than GS, steroids by any route of administration and intra-articular injection of any joint with hyaluronic acid during the previous 6 months.~* Contraindications or special warnings for GS presented in the data sheet.

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Glucosamine Sulfate Group (GS Group) (Type: None): GS Group is treated for at least 6 consecutive months with a single daily dose of 1500 mg of crystalline GS (powder sachets), in addition to conventional therapy.
- Control Group (Type: None): Control Group receive only usual care therapy. The conventional therapy includes exercise for HOA and treatment with acetaminophen or oral NSAIDs or COX-2 inhibitors (150 mg Diclofenac tablets, 20 mg Piroxicam tablets, 550 mg Naproxen tablets, 200 mg Aceclofenac, 600 mg Ibuprofen tablets, 200 mg Celecoxib tablets, 60 mg Etoricoxib tablets).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Role of Mirtazapine in Ameliorating Sleep Disordered Breathing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults with SCI (\>6months after spinal cord injury) at the T6 level/above~* Non-injured adults~Exclusion Criteria:~* Pregnant and lactating females~* Heart failure, vascular disease, or stroke~* Advanced chronic obstructive pulmonary disease (COPD), liver disease, and chronic kidney disease~* BMI \>38 kg/m2~* Mechanical ventilation dependence

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Mirtazapine (Type: ACTIVE_COMPARATOR): The drug will be taken for a one week peroid.
- Placebo (Type: PLACEBO_COMPARATOR): The drug will be taken for a one week peroid.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Post-marketing Observational Study on Risk Factors for Hepatic Encephalopathy in Participants With Unresectable Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participants with unresectable hepatocellular carcinoma who were administered the lenvatinib mesilate for the first time within the registration period.~* Have provided informed consent.~* Underwent case registration by 14 days after the start of administration of drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lenvatinib (Type: None): Participants receiving lenvatinib capsules 12 milligrams (mg) based on participant's body weight greater than or equal to (\>=) 60 kilograms (kg) or 8 mg based on participant's body weight less than (\<) 60 kg, orally, once daily dose will be centrally registered and observed prospectively for up to 1 year after the administration of dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed acute myeloid leukemia (AML) meeting 1 of the following criteria:~  * At least 60 years of age and not a candidate for or refused standard induction treatment~ * Poor risk cytogenetics~ * AML following antecedent hematologic disorder~ * Therapy-related AML~ * Secondary AML~* No granulocytic sarcoma as sole site of disease~* No active CNS disease or CNS relapse~* ECOG performance status 0-2~* Life expectancy \> 6 months~* Total bilirubin \< 2.0 mg/dL~* Creatinine \< 2.0 mg/dL~* AST and ALT \< 2.5 times upper limit of normal~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No NYHA class III or IV congestive heart failure~* No uncontrolled infection~* No history of allergic reactions attributed to compounds of similar chemical or biologic composition to decitabine that are not easily managed~* No other uncontrolled illness including, but not limited to, any of the following:~  * Symptomatic congestive heart failure~ * Unstable angina pectoris~ * Serious cardiac arrhythmia~ * Psychiatric illness or social situations that would preclude compliance with study requirements~* No active second malignancy involving the blood or marrow or likely to progress and require therapy in the next 6 months~* No prior therapy for AML except emergency leukapheresis or hydroxyurea for leukocytosis~* No prior azacitidine or decitabine~* No prior cytarabine or other conventional chemotherapy agents for antecedent hematologic disorders~  * Prior myeloid growth factors, recombinant erythropoietin, thalidomide, or lenalidomide allowed~* No concurrent palliative radiotherapy~* No other concurrent investigational agents~* No other concurrent direct anti-leukemia therapy~* No concurrent combination antiretroviral therapy for HIV-positive patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (chemotherapy) (Type: EXPERIMENTAL): Patients receive decitabine IV over 1 hour on days 1-10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Single Low-Dose of Supplement Amino Acid

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* healthy males and healthy females~* Between 18 and 70 years~Exclusion Criteria:~* Pregnant or nursing~* Taking any chronic medication including birth control pills.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- amino acid supplement (Type: ACTIVE_COMPARATOR): supplements with the proprietary amino acid derivative blend.
- Placebo (Type: PLACEBO_COMPARATOR): Non-Active

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open-Label, Long-Term Extension Study to Evaluate the Safety of CB-03-01 Cream, 1% in Participants With Acne Vulgaris

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participant has successfully completed participation in one of the Phase 3 pivotal studies \[CB-03-01/25 and CB-03-01/26\].~* Participant agrees to use effective method of contraception throughout study, if applicable.~* Participant has provided written informed consent or assent.~* Participant is willing to comply with study instructions and return to the clinic for required visits.~Exclusion Criteria:~* Participant is pregnant, lactating, or is planning to become pregnant during the study.~* Participant has any skin disease or condition that could interfere with the safety evaluation of the test products or requires the use of interfering topical or systemic therapy.~* Participant has any condition which, in the investigator's opinion, would make it unsafe or unsuitable for the participant to participate in this research study.~* Participant plans to use any other investigational drug or device during participation in this study.~* Participant has known hypersensitivity or previous allergic reaction to the drug or any of its ingredients.~* Participant is or plans to use any restricted systemic and/or topical anti-acne preparations or medications during the study

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CB-03-01 cream, 1% (Type: EXPERIMENTAL): CB-03-01 (cortexolone 17α-propionate) Cream, 1%, applied twice daily to whole face (about 1 gram) and affected areas of trunk (if applicable) for up to an additional 9 months. Over the course of the study, treatment on the face and/or trunk may be discontinued if/when acne clears and re-started if/when acne worsens, according to the assessment of the investigator for each respective treatment area.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study to Evaluate the Effect of Nicotinamide Riboside on Immune Activation in Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
* INCLUSION CRITERIA:~Individuals must meet all inclusion criteria listed below in order to be eligible to participate in the study.~* Males and females between the ages of 18 and 80 with mild to moderate active psoriasis.~* Female subjects of child-bearing ability willing to commit to reliable contraception while participating in the study.~* Ability to provide informed consent~* Willingness and ability to participate in required study procedures~EXCLUSION CRITERIA:~* Severe psoriasis by PASI (Psoriasis Area and Severity Index) score \> 12~* Currently being treated with biologic immune modifying agents.~* Currently on treatment for allergies or other inflammatory diseases.~* Currently taking a multivitamin, Vitamin B or tryptophan supplementation and unwilling to stop within 2 weeks of baseline visit.~* Unwillingness/inability to provide informed consent~* ALT \> x3 upper limit of normal, hepatic insufficiency or active liver disease~* Recent history of acute gout~* Chronic renal insufficiency with creatinine \> 2.5mg/dl~* Pregnant (or attempting to become pregnant) women~* Current participation in another drug study~* History of intolerance to NR precursor compounds, including niacin or nicotinamide~* Study adherence concerns~* Individuals with diabetes type 1 and 2 who use insulin~* Women of child-bearing potential unwilling to use contraception or unwilling to practice abstinence~* Breastfeeding women unwilling to stop breastfeeding~* Immunization administered within 30 days of participation and no plans for immunization while participating in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Participants with mild to moderate Psoriasis receiving Placebo (Type: PLACEBO_COMPARATOR): Participants with mild to moderate Psoriasis receiving placebo (2 capsules) twice daily by mouth for 28 days.
- Participants with mild to moderate Psoriasis receiving Nicotinamide Riboside (Type: EXPERIMENTAL): Participants with mild to moderate Psoriasis receiving Nicotinamide Riboside Chloride 500mg (2 capsules) twice daily by mouth for 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults aged 18-55~* Clinically stable Schizophrenia and predominant negative symptoms~* Taking a stable dose of antipsychotic medication~Exclusion Criteria:~* Clinically notable positive symptoms defined by PANSS

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- SPD489 (Lisdexamfetamine dimesylate) (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multicenter Study to Evaluate the Analgesic Efficacy of XP21L in Subjects With Pain Following Bunionectomy Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18-65 years of age~* Have undergone bunionectomy surgery~* Have achieved adequate post-surgical pain~Exclusion Criteria:~* Confounding medical conditions which preclude study participation~* Participated in a study of another investigational drug or device within 30 days prior to randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete